Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.
The firm said that its molecular diagnostics sales growth in the quarter was negatively impacted by non-governmental organization purchasing patterns in Africa.
The company had a profit of £3.4 million, or £0.01 per share, for the year compared to a loss of £9.6 million, or £0.03 per share, the previous year.
The company's clinical services revenues were down 34 percent year over year while product revenues ticked up 7 percent.
Product sales from OEM customers were up 28 percent, while product sales from direct customers and distributors increased 27 percent, and other revenues grew sharply.
The decrease came as improved performance by its biopharma services operations was more than offset by declines in clinical and discovery services revenues.
The company also reported a decline in its net loss for the quarter on lower operating expenses due to a recent reorganization that included layoffs.
The company also reported a jump in its first quarter net loss as operating expenses climbed on higher research and development spending.
Revenues for the quarter were driven by a 27 percent rise in sales volume for the company's OVA1 test.
The firm is conducting validation studies on its lung cancer test and continues to anticipate commercializing it in the second half of this year.